January 18, 2019
Erytech presents poster showing study of eryaspase combination, treatment for pancreatic adenocarcinoma patients
Erytech Pharma today presents poster entitled about A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma, in an event in San Francisco.